Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells
Rachel A. Burga, Nguyễn Tường Vân, Jane Zulovich, et al.
Cytotherapy (2016) Vol. 18, Iss. 11, pp. 1410-1421
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering
May Daher, Katayoun Rezvani
Current Opinion in Immunology (2018) Vol. 51, pp. 146-153
Open Access | Times Cited: 189
Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers
Howell Moffett, Michael Coon, Stefan Radtke, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 155
CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells
Marion Alcantara, Melania Tesio, Carl H. June, et al.
Leukemia (2018) Vol. 32, Iss. 11, pp. 2307-2315
Open Access | Times Cited: 120
Actin Cytoskeleton Remodeling Drives Breast Cancer Cell Escape from Natural Killer–Mediated Cytotoxicity
Antoun Al Absi, Hannah Wurzer, Coralie L. Guérin, et al.
Cancer Research (2018) Vol. 78, Iss. 19, pp. 5631-5643
Open Access | Times Cited: 115
Dysregulation of Chemokine/Chemokine Receptor Axes and NK Cell Tissue Localization during Diseases
Giovanni Bernardini, Fabrizio Antonangeli, Valentina Bonanni, et al.
Frontiers in Immunology (2016) Vol. 7
Open Access | Times Cited: 94
Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia
Concetta Quintarelli, Simona Sivori, Simona Caruso, et al.
Leukemia (2019) Vol. 34, Iss. 4, pp. 1102-1115
Open Access | Times Cited: 81
Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy
Andreia Maia, Mubin Tarannum, Joana R. Lérias, et al.
Cells (2024) Vol. 13, Iss. 5, pp. 451-451
Open Access | Times Cited: 15
Natural killer cells in inflammatory heart disease
SuFey Ong, Noel R. Rose, Daniela Čiháková
Clinical Immunology (2016) Vol. 175, pp. 26-33
Open Access | Times Cited: 84
Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer
Shabnum Patel, Rachel A. Burga, Allison B. Powell, et al.
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 57
Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an “Off-the-Shelf Immunotherapy” for Improvement in Cancer Treatment
Olaf Oberschmidt, Stephan Kloeß, Ulrike Koehl
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 57
Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy
Faroogh Marofi, Heshu Sulaiman Rahman, Lakshmi Thangavelu, et al.
Stem Cell Research & Therapy (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 37
Targeting TDO in cancer immunotherapy
Chengpeng Yu, Yunlei Song, Zhengming Zhu, et al.
Medical Oncology (2017) Vol. 34, Iss. 5
Closed Access | Times Cited: 43
Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro
Yoshitaka Tanaka, Tsutomu Nakazawa, Mitsutoshi Nakamura, et al.
PLoS ONE (2019) Vol. 14, Iss. 3, pp. e0212455-e0212455
Open Access | Times Cited: 38
Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival
Matthew Alderdice, Philip D. Dunne, Aidan Cole, et al.
Modern Pathology (2017) Vol. 30, Iss. 9, pp. 1287-1298
Open Access | Times Cited: 29
Designing Magnetically Responsive Biohybrids Composed of Cord Blood-Derived Natural Killer Cells and Iron Oxide Nanoparticles
Rachel A. Burga, Md. Daud Hossain Khan, Nitin Agrawal, et al.
Bioconjugate Chemistry (2019) Vol. 30, Iss. 3, pp. 552-560
Closed Access | Times Cited: 29
Characterization and Potential Applications of Dog Natural Killer Cells in Cancer Immunotherapy
Alicia A. Gingrich, Jaime F. Modiano, Robert J. Canter
Journal of Clinical Medicine (2019) Vol. 8, Iss. 11, pp. 1802-1802
Open Access | Times Cited: 29
The rise of human stem cell-derived natural killer cells for cancer immunotherapy
Kejian Wang, Yue Han, William C. Cho, et al.
Expert Opinion on Biological Therapy (2018) Vol. 19, Iss. 2, pp. 141-148
Closed Access | Times Cited: 23
Telomerase Reverse Transcriptase Increases Proliferation and Lifespan of Human NK Cells without Immortalization
Maria A. Streltsova, Maria O. Ustiuzhanina, Eugene V. Barsov, et al.
Biomedicines (2021) Vol. 9, Iss. 6, pp. 662-662
Open Access | Times Cited: 14
Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy
Zhu Huang, Dan S. Kaufman
Blood Science (2019) Vol. 1, Iss. 1, pp. 4-11
Open Access | Times Cited: 15
Photothermal therapy co-localized with CD137 agonism improves survival in an SM1 melanoma model without hepatotoxicity
Jacob A. Medina, Debbie K. Ledezma, Joshua Ghofrani, et al.
Nanomedicine (2024) Vol. 19, Iss. 25, pp. 2049-2064
Open Access | Times Cited: 1
CAR-engineered NK cells versus CAR T cells in treatment of glioblastoma; strength and flaws
Mohammadmahdi Sabahi, Ali Fathi Jouzdani, Zohre Sadeghian, et al.
Journal of Neuro-Oncology (2024) Vol. 171, Iss. 3, pp. 495-530
Closed Access | Times Cited: 1
Natural killer cells and cancer therapy, what we know and where we are going
Faezeh Ghaemdoust, Mahsa Keshavarz‐Fathi, Nima Rezaei
Immunotherapy (2019) Vol. 11, Iss. 14, pp. 1231-1251
Closed Access | Times Cited: 10
Chimeric antigen receptor-natural killer cells: a promising sword against insidious tumor cells
Tahereh Hojjatipour, Zahra Sharifzadeh, Amirhosein Maali, et al.
Human Cell (2023) Vol. 36, Iss. 6, pp. 1843-1864
Closed Access | Times Cited: 3
Gene-modified, cell-based therapies—an overview
Allison B. Powell, Kiara Williams, Conrad Russell Y. Cruz
Cytotherapy (2016) Vol. 18, Iss. 11, pp. 1351-1359
Closed Access | Times Cited: 5
Cancer Immunotherapy Via Stem Cell-Derived NK Cells
Fatemeh Hosseini, Mohammad Ahmadvand, Roya Karimi, et al.
Immunotherapy (2023) Vol. 15, Iss. 12, pp. 963-973
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top